UPDATE: Wedbush Raises PT to $32 on Pacira Pharmaceuticals on Long-Term Outlook

Wedbush maintained Pacira Pharmaceuticals (NASDAQ: PCRX ) with an Outperform rating and raised the price target from $23.00 to $32.00. Wedbush said, "As already preannounced, PCRX reported Q4 EXPAREL sales of $7.8MM, ahead of our original $7.0MM estimate. Q4 total revenues were $10.5MM and GAAP EPS loss was ($0.50) versus